DPC Stock Soars 67% In 3Q On Strength Of Immulite Sales, IVD Market Growth
This article was originally published in The Gray Sheet
Executive Summary
Solid sales of Diagnostic Products Corp.' s reagents for the Immulite immunoassay platform, combined with revived growth in the immunoassay segment of the in vitro diagnostic market triggered a 67.2% gain in the company's stock price during the third quarter of 2000.